Pulmonary hypertension (PH) in patients (pts) with CML treated with tyrosine kinase inhibitors (TKIs).

6597 Background: TKIs are the current standard therapy for patients with CML. Fluid retention and pleural effusions have been reported in pts treated with TKIs, particularly with dasatinib. Although TKIs have been shown to reverse PH in animal models, there have been some reports of development of reversible PH with dasatinib. Methods: We conducted a retrospective analysis on 401 CML pts in CP who were treated with TKIs (imatinib, dasatinib or nilotinib) as initial therapy for CML and had a transthoracic echocardiogram done (TTE) at some point during the course of therapy. PH was diagnosed if the patient had an estimated right ventricular systolic pressure (RVSP) of 35 mm Hg or greater. Secondary causes of PH (systolic or diastolic dysfunction on TTE, chronic obstructive pulmonary diseases [COPD], obstructive sleep apnea [OSA] and pulmonary embolism) were investigated during chart review. Results: Twenty pts had at least one TTE; median age 57 years, 46% males. Six pts (30%) received nilotinib 400 mg BID,...